Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TJ079
- Development stage
- Preclinical
- Lead developer
- Tuojie Biotech
- Modality
- Small Molecules
01
Overview
TJ079 is a small molecule therapeutic candidate currently in the IND-enabling stage for the treatment of heart failure (HF). Developed by Tuojie Biotech (Suzhou), the compound is part of a pipeline focused on cardiovascular and metabolic diseases. While the specific biological target has not been publicly disclosed by the sponsor, the drug is being positioned as a potential treatment for heart failure, a condition characterized by the heart's inability to pump sufficient blood to meet the body's needs. It is distinct from the oncology drug enoblituzumab, which has also been referred to by the code name TJ079 in the context of other sponsor pipelines (e.g., I-Mab Biopharma).
- Other names
- TJ079TJ-079TJ 079
Beyond the preview
Go deeper on TJ079.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TJ079.